Borrelia burgdorferi immunoglobulin G (IgG) antibody IVD, kit, enzyme immunoassay (EIA)

Borrelia burgdorferi IgG antibody IVD kits use enzyme immunoassay (EIA) technology to detect immunoglobulin G (IgG) antibodies in patient samples, helping confirm or rule out Lyme disease caused by *Borrelia burgdorferi* bacteria. These tests analyze clinical specimens like serum or plasma to identify immune responses, aiding in early diagnosis or monitoring of infection progression. Clinicians rely on these results alongside patient history and symptoms to guide treatment decisions. The assays are designed for laboratory use, providing objective, standardized measurements of antibody presence.

These kits are typically regulated as in vitro diagnostics (IVDs) and may require validation for accuracy, precision, and clinical performance before market authorization. They are supplied as complete test systems, including reagents, controls, and instructions, often requiring specialized laboratory equipment. Compliance with standards like ISO 15189 or FDA 21 CFR Part 820 may apply depending on the jurisdiction. Availability varies by region, with some tests approved for screening while others serve confirmatory purposes.